Trotabresib, also known as CC-90010 and BMS-986378, is a novel, oral, reversible, small-molecule BET inhibitor. Trotabresib binds to the bromodomains of BET proteins (BRD2, BRD3, BRD4, and BRDT), disrupting their interaction with acetylated histones. This inhibition leads to suppression of oncogene transcription, particularly affecting MYC, BCL-2, and other genes involved in tumor progression.Trotabresib has shown potent antiproliferative effects in multiple cancer models, including hematologic malignancies and solid tumors. Preclinical and clinical studies indicate activity in glioblastoma, non-Hodgkin’s lymphoma, and other aggressive tumors. Inhibition of BRD4 by Trotabresib can lead to apoptosis and cell cycle arrest in tumor cells.
MedKoo Cat#: 208412
Name: Trotabresib
CAS#: 1706738-98-8
Chemical Formula: C21H21NO4S
Exact Mass: 383.1191
Molecular Weight: 383.46
Elemental Analysis: C, 65.78; H, 5.52; N, 3.65; O, 16.69; S, 8.36
The following data is based on the product molecular weight 383.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
